May 7, 2020 / 1:26 PM / a month ago

BRIEF-Evelo Biosciences Says Submitted IND For Study Of EDP1815 In COVID-19 Patients

May 7 (Reuters) - Evelo Biosciences Inc:

* EVELO BIOSCIENCES, RUTGERS UNIVERSITY, AND ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL ANNOUNCE SUBMISSION OF IND FOR A PHASE 2 STUDY OF EDP1815 IN COVID-19 PATIENTS

* EVELO BIOSCIENCES INC - EDP1815 HAS DEMONSTRATED FAVORABLE TOLERABILITY AND ANTI-INFLAMMATORY ACTIVITY IN A PRIOR CLINICAL TRIAL

* EVELO BIOSCIENCES INC - STUDY DATA EXPECTED DURING 2H 2020

* EVELO BIOSCIENCES INC - EARLY INTERVENTION OF TREATMENT IN HOSPITALIZED PATIENTS COULD HELP PREVENT PROGRESSION OF DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below